SEC Company Response from IRADIMED CORP (IRMD) (CIK 0001325618) (IRMD) — Jul 9, 2014
IRADIMED CORP (IRMD) (CIK 0001325618)
Date: July 9, 2014 · CIK: 0001325618 · Accession: 0001104659-14-050642
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-196875
Referenced dates: June 16, 2014
Letter
Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: iRadimed Corporation Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-196875) Filed July 9, 2014 CIK No. 00013525618
Dear Ms. Ravitz:
On behalf of iRadimed Corporation, a Delaware corporation (the “Company”, “we”, “us”, “our”), the undersigned is hereby providing the Company’s response to the Securities and Exchange Commission’s (the “Commission”) oral comment provided by Mr. Brian Soares on behalf of the Commission Staff on June 24, 2014 during a telephone conference with Mr. Anh Tran of K&L Gates LLP. The oral comment noted that that revisions to the Company’s Registration Statement filed with the Commission on June 18, 2014 in response to Comment No. 2 in the Commission’s letter dated June 16, 2014 were made in the Use of Proceeds section starting on page 32 but were not made to the Prospectus Summary section starting on page 1. We respectfully note the comment and have revised the disclosures in the Prospectus Summary to conform to the disclosures in the Use of Proceeds section.
Should you have any questions or require any additional information, please contact K&L Gates LLP, attention Anh Q. Tran, Esq., by phone at (310) 552-5083, by facsimile at (310) 552-5007, or by e-mail at anh.tran@klgates.com.
Sincerely,
K&L Gates LLP
Show Raw Text
CORRESP 1 filename1.htm July 9, 2014 Via EDGAR Amanda Ravitz Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: iRadimed Corporation Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-196875) Filed July 9, 2014 CIK No. 00013525618 Dear Ms. Ravitz: On behalf of iRadimed Corporation, a Delaware corporation (the “Company”, “we”, “us”, “our”), the undersigned is hereby providing the Company’s response to the Securities and Exchange Commission’s (the “Commission”) oral comment provided by Mr. Brian Soares on behalf of the Commission Staff on June 24, 2014 during a telephone conference with Mr. Anh Tran of K&L Gates LLP. The oral comment noted that that revisions to the Company’s Registration Statement filed with the Commission on June 18, 2014 in response to Comment No. 2 in the Commission’s letter dated June 16, 2014 were made in the Use of Proceeds section starting on page 32 but were not made to the Prospectus Summary section starting on page 1. We respectfully note the comment and have revised the disclosures in the Prospectus Summary to conform to the disclosures in the Use of Proceeds section. Should you have any questions or require any additional information, please contact K&L Gates LLP, attention Anh Q. Tran, Esq., by phone at (310) 552-5083, by facsimile at (310) 552-5007, or by e-mail at anh.tran@klgates.com. Sincerely, K&L Gates LLP /s/ Anh Q. Tran, Esq. Anh Q. Tran, Esq. cc: Brian Soares, Commission Roger Susi, Chief Executive Officer, Iradimed Corporation Chris Scott, Chief Financial Officer, Iradimed Corporation Leib Orlanski, K&L Gates LLP